GSK's Twice-Yearly Depemokimab Reduces Nasal Polyp Size, Goes Under FDA Review

On Monday, the Food and Drug Administration (FDA) accepted for review GSK plc’s GSK marketing application for depemokimab in two indications.The company released topline data from the trials in October 2024.The proposed indications are as add-on maintenance treatment of asthma in adult and pediatric patients aged 12 years and older with type 2 inflammation characterized by an eosinophilic phenotype on medium- to high-dose inhaled corticosteroids (ICS) plus another asthma controller and, as add-on maintenanc ...